

# Study explores a novel candidate for antidepressant treatment

January 17 2018

---



Julia Castello and Lauren Malave. Credit: City College of New York

According to the World Health Organization more than three hundred million people worldwide are affected by major depressive disorder. Unfortunately, the antidepressants commonly used to treat them only work for 50% of the population.

A recent paper published in the journal *Molecular Psychiatry* explores how a protein named CK2 could be playing a key role. The lead author of the paper, Julia Castello, is a biochemistry student at the Graduate Center, CUNY working in Eitan Friedman's neuroscience lab at The City College of New York.

As the research points out, the most used antidepressants are called Selective Serotonin Reuptake Inhibitors (SSRIs). The problem is that there are fourteen different types of serotonin receptors, but it is not known which are the mediators of the therapeutic effect of SSRIs. Castello, along with her team, are the first ones to identify CK2 as a modulator of a [serotonin receptor](#), 5-HT<sub>4</sub>. Manipulation of CK2 in the brain decreases depressive and anxious states through the 5-HT<sub>4</sub> receptor.

Castello says: "Identifying new targets broadens our understanding about the cause of depression as well as the mechanism of action of antidepressants, which could lead to the formulation of new antidepressants that work more efficiently and faster for more people."

A separate study of CK2's potential role in Parkinson's is the subject of another research project at City College. Its findings, published in the *Journal of Neuroscience* in December, identify CK2 as a major player in the molecular mechanisms and targets that contribute to modulate L-DOPA induced dyskinesia. L-DOPA is currently the most effective medication available in the market. But a side effect of this drug is that after years of treatment, patients develop involuntary movements that can be debilitating.

**More information:** J Castello et al, CK2 regulates 5-HT<sub>4</sub> receptor signaling and modulates depressive-like behavior, *Molecular Psychiatry* (2017). [DOI: 10.1038/mp.2017.240](https://doi.org/10.1038/mp.2017.240)

Marisol Cortés et al. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors, *The Journal of Neuroscience* (2017). [DOI: 10.1523/JNEUROSCI.0443-17.2017](https://doi.org/10.1523/JNEUROSCI.0443-17.2017)

Provided by City College of New York

Citation: Study explores a novel candidate for antidepressant treatment (2018, January 17)  
retrieved 25 April 2024 from

<https://medicalxpress.com/news/2018-01-explores-candidate-antidepressant-treatment.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.